Login to Your Account



Halozyme's Drug Platform Hits Snag, Now on the Turnaround

By Brian Orelli
BioWorld Insight Contributing Writer

Monday, October 1, 2012

When Halozyme Therapeutics Inc. received word that the FDA was issuing a complete response letter for HyQ, the news wasn't isolated to just the program that it's developing with Baxter International Inc. The FDA also put a temporary clinical hold on a subcutaneous version of ViroPharma Inc.'s Cinryze (C1 esterase inhibitor [human]). (See BioWorld Today, Aug. 3, 2012.)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription